Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2025-2034
Description
The global non-steroidal anti-inflammatory drugs (NSAIDs) market attained a value of USD 21.70 Billion in 2024, driven by a shift from opioid analgesics use of NSAIDs and enhancing client’s knowledge of their side effects across the globe. The market is further expected to grow at a CAGR of 5.40% between 2025 and 2034 to reach a value of USD 36.72 Billion by 2034.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to alleviate pain, inflammation, and fever. Chronic pain being a long-term problem, that worsens health and economic issues due to reduced productivity and higher health costs. NSAIDs work by reducing prostaglandins (compounds that involved in causing pain and inflammation). These drugs help manage pain from arthritis, muscle pain, headache, premenstrual menstrual cramps, and injuries like sprains and strains. They are available without over the counter as common pain relievers like ibuprofen (Advil, Motrin) and naproxen (Aleve), and by prescription. Most NSAIDs are taken orally, but some are available as creams and gels for direct application to the skin to relieve localized pain.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Drivers
Increasing Utilization of NSAIDs to Treat Multiple Conditions
With strong research and development investments, the global market for NSAIDs is set to grow in the forecast period. This growth is impacted by rising incidence of diseases that cause pain and inflammation. Bone and joint-related issues like rheumatoid arthritis and osteoarthritis comprise a major share wherein NSAIDs are used. In addition, surge in surgical procedures in hospitals is leading increased adoption of NSAIDs. Pain disorders and the aging population prone to various diseases are also increasing the need for the drugs. Additionally, rising support for pain management from end-users, helped by government and healthcare policies, ensures market expansion.
Increased Preference Over Opioids to Boost the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Demand
Despite the widespread use of opioids for pain relief, there is a growing trend towards prescribing NSAIDs due to the harmful effects of opioids. This has led to a push for safer pain management options. The American Academy of Family Physicians advises over-the-counter drugs like ibuprofen and naproxen as the primary treatment for mild to moderate pain. Such recommendations are likely to further boost the NSAIDs market value in the forecast period.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends
Changes in Drug Formulation to Boost Efficacy
Both healthcare professionals and consumers are increasingly concerned about the long-term side effects of NSAID medication and therapy. This has led to better measures to balance risk and boost its efficacy to provide improved patient outcomes.
Rising Sports-Related Injuries
As more people engage in sports and exercise, the rate of sport-related injuries has increased. Doctors often prescribe topical NSAIDs for these injuries because they effectively treat localized pain and inflammation. Therefore, the use of topical NSAIDs is rapidly growing in sports medicine and physical therapy.
Investments to Provide Effective Healthcare Facilities
Improving healthcare facilities and related infrastructures are major market trends boosting market growth. More business associations and joint ventures are focusing on funding and adoption modern technologies, with both public and private organizations leading the way.
Over-the-counter (OTC) Availability and Convenience
Common NSAIDs are available over the counter (OTC), making them accessible without a prescription. This easy access leads consumers to seek quick relief from pain. Forms like gels, creams, and patches allow individuals to use NSAIDs easily without needing a doctor's consultation.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation
The EMR’s report titled “Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Indication Naproxen
Celecoxib
Others Daypro
Indocin
Lodine
Naprosyn
Relafen
Vimovo
Voltaren
Market Breakup by Route of Administration
Arthritis Stands as the Most Dominant Category for the Forecast Period
The market segmentation based on disease indications is divided into arthritis, migraine, ophthalmic diseases, and others. Arthritis, including osteoarthritis and rheumatoid arthritis, is estimated to lead the market share in the forecast period. With chronic pain and inflammation as a common symptom, NSAID prescriptions are commonly referred by medical professionals. Ibuprofen-based products are especially popular because they work well and are easy to get. The rising prevalence of arthritis, especially in an aging population, significantly influences the NSAIDs market. NSAIDs also treat headaches and eye disorders, further boosting market growth. Ongoing research aims to meet the diverse needs of patients and healthcare providers.
Ibuprofen is Leading the Market Share Based on Drug Types
The market segmentation by drugs encompasses various drugs, which include over-the-counter drugs (Aspirin, Ibuprofen, Naproxen, Naproxen, Celecoxib, Others) and prescription (Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, Voltaren). Ibuprofen, an OTC medication, leads the market, due to its effectiveness in treating pain and inflammation. Its various formulations cater to different patient needs. Despite this, ibuprofen is preferred over aspirin for its wider usage across different ages and therapies. Research, policy changes, and new competitors may impact the market by either reducing ibuprofen’s market share or providing opportunities for new competitors to emerge.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market by Region
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are all included in the regional market analysis. North America holds a substantial market share for NSAIDs because of the large population and common health issues such as arthritis and chronic pain present in this region. Developed nations ensure the availability of these drugs in healthcare facilities. Proper advertising informs customers about these products. Regulatory agencies such as the Food and Drug Administration in the USA and Health Canada inspect and verify NSAIDs' safety and efficacy before and after market approval.
In Asia Pacific region, many large companies manufacture and distribute NSAIDs, with strong research efforts to ensure quality and safety. Asia Pacific, with its large population and increasing arthritis cases, is expected to witness rapid growth in the forecast period. Government policies on treatment pricing and coverage, along with economic development in Southeast Asia and South Asia greatly influence demand.
Recent Developments in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
In March 2024, Endo International plc launched the first flu pill. It is called ibuprofen-famotidine 800 mg/26. They launched it through their subsidiaries Par Pharmaceutical, Inc. This new generic medication, DUEXIS®, treats rheumatoid arthritis and osteoarthritis. It also reduces the risk of ulcers in the stomach and upper intestine that come from ibuprofen. This innovation offers better treatment options for arthritis patients. It shows Endo International’s commitment to advancing drugs.
In May 2023, AbbVie got approval from the U. S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib). It's a new treatment for adults with moderately to severely active Crohn’s disease. This approval is expected to greatly impact the treatment of Crohn’s disease. It will give patients a new treatment choice and improve their quality of life. It is also likely to boost AbbVie’s revenues.
In January 2023, Sun Pharma acquired three brands from Aksigen Hospital Care, namely Disperzyme, Disperzyme-CD, and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg), and Rutoside Trihydrate 100 mg. This acquisition is strategic and aims to improve Sun Pharma’s anti-inflammatory medicine range. It will provide more treatment options for patients. Sun Pharma hopes to use these well-known brands and to expand its market in anti-inflammatory drugs.
Leading Players in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
The key features of the market report include patent analysis, and strategic initiatives such as partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:
Bayer AG
It is a Germany-based company that offers various NSAIDs including Aspirin (Bayer®, St. Joseph®). Ibuprofen (Motrin®, Advil®). Naproxen sodium (Aleve®)
Novartis AG
Established in 1996 and headquartered in Switzerland, the company is involved in the production of various medications, including NSAIDs. One notable NSAID produced by Novartis is Diclofenac.
Pfizer Inc.
The company was established in 1849 and has its base in New York. It deals with various NASID products like Celecoxib, and Ibuprofen.
Johnson & Johnson Private Limited
Based in the U.S., this company was founded in 1957. The company produces various NSAIDs which include Naproxen, Diclofenac,
Other companies in the market include Assertio Holdings, Inc., Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, and Sanofi India Limited.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to alleviate pain, inflammation, and fever. Chronic pain being a long-term problem, that worsens health and economic issues due to reduced productivity and higher health costs. NSAIDs work by reducing prostaglandins (compounds that involved in causing pain and inflammation). These drugs help manage pain from arthritis, muscle pain, headache, premenstrual menstrual cramps, and injuries like sprains and strains. They are available without over the counter as common pain relievers like ibuprofen (Advil, Motrin) and naproxen (Aleve), and by prescription. Most NSAIDs are taken orally, but some are available as creams and gels for direct application to the skin to relieve localized pain.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Growth Drivers
Increasing Utilization of NSAIDs to Treat Multiple Conditions
With strong research and development investments, the global market for NSAIDs is set to grow in the forecast period. This growth is impacted by rising incidence of diseases that cause pain and inflammation. Bone and joint-related issues like rheumatoid arthritis and osteoarthritis comprise a major share wherein NSAIDs are used. In addition, surge in surgical procedures in hospitals is leading increased adoption of NSAIDs. Pain disorders and the aging population prone to various diseases are also increasing the need for the drugs. Additionally, rising support for pain management from end-users, helped by government and healthcare policies, ensures market expansion.
Increased Preference Over Opioids to Boost the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Demand
Despite the widespread use of opioids for pain relief, there is a growing trend towards prescribing NSAIDs due to the harmful effects of opioids. This has led to a push for safer pain management options. The American Academy of Family Physicians advises over-the-counter drugs like ibuprofen and naproxen as the primary treatment for mild to moderate pain. Such recommendations are likely to further boost the NSAIDs market value in the forecast period.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends
Changes in Drug Formulation to Boost Efficacy
Both healthcare professionals and consumers are increasingly concerned about the long-term side effects of NSAID medication and therapy. This has led to better measures to balance risk and boost its efficacy to provide improved patient outcomes.
Rising Sports-Related Injuries
As more people engage in sports and exercise, the rate of sport-related injuries has increased. Doctors often prescribe topical NSAIDs for these injuries because they effectively treat localized pain and inflammation. Therefore, the use of topical NSAIDs is rapidly growing in sports medicine and physical therapy.
Investments to Provide Effective Healthcare Facilities
Improving healthcare facilities and related infrastructures are major market trends boosting market growth. More business associations and joint ventures are focusing on funding and adoption modern technologies, with both public and private organizations leading the way.
Over-the-counter (OTC) Availability and Convenience
Common NSAIDs are available over the counter (OTC), making them accessible without a prescription. This easy access leads consumers to seek quick relief from pain. Forms like gels, creams, and patches allow individuals to use NSAIDs easily without needing a doctor's consultation.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation
The EMR’s report titled “Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Indication
- Arthritis
- Migraine
- Ophthalmic Diseases
- Others
- Over-the-Counter Drugs
- Aspirin
- Ibuprofen
- Prescription
Market Breakup by Route of Administration
- Oral
- Parenteral
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Arthritis Stands as the Most Dominant Category for the Forecast Period
The market segmentation based on disease indications is divided into arthritis, migraine, ophthalmic diseases, and others. Arthritis, including osteoarthritis and rheumatoid arthritis, is estimated to lead the market share in the forecast period. With chronic pain and inflammation as a common symptom, NSAID prescriptions are commonly referred by medical professionals. Ibuprofen-based products are especially popular because they work well and are easy to get. The rising prevalence of arthritis, especially in an aging population, significantly influences the NSAIDs market. NSAIDs also treat headaches and eye disorders, further boosting market growth. Ongoing research aims to meet the diverse needs of patients and healthcare providers.
Ibuprofen is Leading the Market Share Based on Drug Types
The market segmentation by drugs encompasses various drugs, which include over-the-counter drugs (Aspirin, Ibuprofen, Naproxen, Naproxen, Celecoxib, Others) and prescription (Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, Voltaren). Ibuprofen, an OTC medication, leads the market, due to its effectiveness in treating pain and inflammation. Its various formulations cater to different patient needs. Despite this, ibuprofen is preferred over aspirin for its wider usage across different ages and therapies. Research, policy changes, and new competitors may impact the market by either reducing ibuprofen’s market share or providing opportunities for new competitors to emerge.
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market by Region
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa are all included in the regional market analysis. North America holds a substantial market share for NSAIDs because of the large population and common health issues such as arthritis and chronic pain present in this region. Developed nations ensure the availability of these drugs in healthcare facilities. Proper advertising informs customers about these products. Regulatory agencies such as the Food and Drug Administration in the USA and Health Canada inspect and verify NSAIDs' safety and efficacy before and after market approval.
In Asia Pacific region, many large companies manufacture and distribute NSAIDs, with strong research efforts to ensure quality and safety. Asia Pacific, with its large population and increasing arthritis cases, is expected to witness rapid growth in the forecast period. Government policies on treatment pricing and coverage, along with economic development in Southeast Asia and South Asia greatly influence demand.
Recent Developments in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
In March 2024, Endo International plc launched the first flu pill. It is called ibuprofen-famotidine 800 mg/26. They launched it through their subsidiaries Par Pharmaceutical, Inc. This new generic medication, DUEXIS®, treats rheumatoid arthritis and osteoarthritis. It also reduces the risk of ulcers in the stomach and upper intestine that come from ibuprofen. This innovation offers better treatment options for arthritis patients. It shows Endo International’s commitment to advancing drugs.
In May 2023, AbbVie got approval from the U. S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib). It's a new treatment for adults with moderately to severely active Crohn’s disease. This approval is expected to greatly impact the treatment of Crohn’s disease. It will give patients a new treatment choice and improve their quality of life. It is also likely to boost AbbVie’s revenues.
In January 2023, Sun Pharma acquired three brands from Aksigen Hospital Care, namely Disperzyme, Disperzyme-CD, and Phlogam (Trypsin BP 48 mg, Bromelain 90 mg), and Rutoside Trihydrate 100 mg. This acquisition is strategic and aims to improve Sun Pharma’s anti-inflammatory medicine range. It will provide more treatment options for patients. Sun Pharma hopes to use these well-known brands and to expand its market in anti-inflammatory drugs.
Leading Players in the Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
The key features of the market report include patent analysis, and strategic initiatives such as partnerships, and collaborations analysis by the leading players. The major companies in the market are as follows:
Bayer AG
It is a Germany-based company that offers various NSAIDs including Aspirin (Bayer®, St. Joseph®). Ibuprofen (Motrin®, Advil®). Naproxen sodium (Aleve®)
Novartis AG
Established in 1996 and headquartered in Switzerland, the company is involved in the production of various medications, including NSAIDs. One notable NSAID produced by Novartis is Diclofenac.
Pfizer Inc.
The company was established in 1849 and has its base in New York. It deals with various NASID products like Celecoxib, and Ibuprofen.
Johnson & Johnson Private Limited
Based in the U.S., this company was founded in 1957. The company produces various NSAIDs which include Naproxen, Diclofenac,
Other companies in the market include Assertio Holdings, Inc., Amgen Inc., Lion Corporation, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, and Sanofi India Limited.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in the Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report
- What was the global non-steroidal anti-inflammatory drugs (NSAIDs) market value in 2024?
- What is the global non-steroidal anti-inflammatory drugs (NSAIDs) market forecast outlook for 2025-2034?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- What is the market segmentation based on disease indication?
- What is the market breakup based on drugs?
- What is the market segmentation based on route of administration?
- What are major distribution channels in the market?
- What are the regional markets covered in the EMR report?
- What are the major factors aiding the global non-steroidal anti-inflammatory drugs (NSAIDs) market demand?
- Which country is expected to experience expedited growth during the forecast period?
- What are the implications of rising online pharmacy sales for the distribution of NSAIDs, and how do traditional pharmacies respond to this trend?
- What are the major global non-steroidal anti-inflammatory drugs (NSAIDs) market trends?
- How does the rise in the geriatric population impact the market size?
- What are the safety and efficacy concerns associated with long-term NSAID use, and how do they influence prescribing decisions?
- Who are the key players involved in the non-steroidal anti-inflammatory drugs (NSAIDs) market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the leading disease indications driving the non-steroidal anti-inflammatory drugs (NSAIDs) market demand?
- Which NSAID drugs dominate the over-the-counter segment, and what factors contribute to their popularity?
- What are the primary distribution channels through which NSAIDs are distributed to consumers, and how does each channel contribute to market penetration?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Overview
- 3.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Historical Value (2018-2024)
- 3.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Landscape*
- 5.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Product Landscape
- 5.2.1 Analysis by Disease Indication
- 5.2.2 Analysis by Route of Administration
- 6 Global Infectious Diseases Epidemiology Snapshot
- 6.1 Global Infectious Disease Incidence Number Overview (2018-2034)
- 6.2 Global Infectious Disease Incidence – by Disease (2018-2034)
- 6.2.1 Arthritis
- 6.2.2 Migraine
- 6.2.3 Ophthalmic Diseases
- 7 Global Non- Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Dynamics
- 7.1 Market Drivers and Constraints
- 7.2 SWOT Analysis
- 7.2.1 Strengths
- 7.2.2 Weaknesses
- 7.2.3 Opportunities
- 7.2.4 Threats
- 7.3 PESTEL Analysis
- 7.3.1 Political
- 7.3.2 Economic
- 7.3.3 Social
- 7.3.4 Technological
- 7.3.5 Legal
- 7.3.6 Environment
- 7.4 Porter’s Five Forces Model
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of New Entrants
- 7.4.4 Threat of Substitutes
- 7.4.5 Degree of Rivalry
- 7.5 Key Demand Indicators
- 7.6 Key Price Indicators
- 7.7 Industry Events, Initiatives, and Trends
- 7.8 Value Chain Analysis
- 8 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market Segmentation (218-2034)
- 8.1 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 8.1.1 Market Overview
- 8.1.2 Arthritis
- 8.1.3 Migraine
- 8.1.4 Ophthalmic Diseases
- 8.1.5 Others
- 8.2 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 8.2.1 Over-the-Counter Drugs
- 8.2.1.1 Aspirin
- 8.2.1.2 Ibuprofen
- 8.2.1.3 Naproxen
- 8.2.1.4 Naproxen
- 8.2.1.5 Celecoxib
- 8.2.1.6 Others
- 8.2.2 Prescription
- 8.2.2.1 Daypro
- 8.2.2.2 Indocin
- 8.2.2.3 Lodine
- 8.2.2.4 Naprosyn
- 8.2.2.5 Relafen
- 8.2.2.6 Vimovo
- 8.2.2.7 Voltaren
- 8.3 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 8.3.1 Market Overview
- 8.3.2 Oral
- 8.3.3 Parenteral
- 8.4 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 8.4.1 Market Overview
- 8.4.2 Hospital Pharmacy
- 8.4.3 Retail Pharmacy
- 8.4.4 Online Pharmacy
- 8.4.5 Others
- 8.5 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Region
- 8.5.1 Market Overview
- 8.5.2 North America
- 8.5.3 Europe
- 8.5.4 Asia Pacific
- 8.5.5 Latin America
- 8.5.6 Middle East and Africa
- 9 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (218-2034)
- 9.1 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 9.1.1 Market Overview
- 9.1.2 Arthritis
- 9.1.3 Migraine
- 9.1.4 Ophthalmic Diseases
- 9.1.5 Others
- 9.2 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 9.2.1 Over-the-Counter Drugs
- 9.2.1.1 Aspirin
- 9.2.1.2 Ibuprofen
- 9.2.1.3 Naproxen
- 9.2.1.4 Naproxen
- 9.2.1.5 Celecoxib
- 9.2.1.6 Others
- 9.2.2 Prescription
- 9.2.2.1 Daypro
- 9.2.2.2 Indocin
- 9.2.2.3 Lodine
- 9.2.2.4 Naprosyn
- 9.2.2.5 Relafen
- 9.2.2.6 Vimovo
- 9.2.2.7 Voltaren
- 9.3 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 9.3.1 Market Overview
- 9.3.2 Oral
- 9.3.3 Parenteral
- 9.4 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 9.4.1 Market Overview
- 9.4.2 Hospital Pharmacy
- 9.4.3 Retail Pharmacy
- 9.4.4 Online Pharmacy
- 9.4.5 Others
- 9.5 North America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Country
- 9.5.1 United States of America
- 9.5.2 Canada
- 10 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (218-2034)
- 10.1 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 10.1.1 Market Overview
- 10.1.2 Arthritis
- 10.1.3 Migraine
- 10.1.4 Ophthalmic Diseases
- 10.1.5 Others
- 10.2 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 10.2.1 Over-the-Counter Drugs
- 10.2.1.1 Aspirin
- 10.2.1.2 Ibuprofen
- 10.2.1.3 Naproxen
- 10.2.1.4 Celecoxib
- 10.2.1.5 Others
- 10.2.2 Prescription
- 10.2.2.1 Daypro
- 10.2.2.2 Indocin
- 10.2.2.3 Lodine
- 10.2.2.4 Naprosyn
- 10.2.2.5 Relafen
- 10.2.2.6 Vimovo
- 10.2.2.7 Voltaren
- 10.3 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 10.3.1 Market Overview
- 10.3.2 Oral
- 10.3.3 Parenteral
- 10.4 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 10.4.1 Market Overview
- 10.4.2 Hospital Pharmacy
- 10.4.3 Retail Pharmacy
- 10.4.4 Online Pharmacy
- 10.4.5 Others
- 10.5 Europe Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Country
- 10.5.1 United Kingdom
- 10.5.2 Germany
- 10.5.3 France
- 10.5.4 Italy
- 10.5.5 Others
- 11 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (218-2034)
- 11.1 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 11.1.1 Market Overview
- 11.1.2 Arthritis
- 11.1.3 Migraine
- 11.1.4 Ophthalmic Diseases
- 11.1.5 Others
- 11.2 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 11.2.1 Over-the-Counter Drugs
- 11.2.1.1 Aspirin
- 11.2.1.2 Ibuprofen
- 11.2.1.3 Naproxen
- 11.2.1.4 Naproxen
- 11.2.1.5 Celecoxib
- 11.2.1.6 Others
- 11.2.2 Prescription
- 11.2.2.1 Daypro
- 11.2.2.2 Indocin
- 11.2.2.3 Lodine
- 11.2.2.4 Naprosyn
- 11.2.2.5 Relafen
- 11.2.2.6 Vimovo
- 11.2.2.7 Voltaren
- 11.3 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 11.3.1 Market Overview
- 11.3.2 Oral
- 11.3.3 Parenteral
- 11.4 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 11.4.1 Market Overview
- 11.4.2 Hospital Pharmacy
- 11.4.3 Retail Pharmacy
- 11.4.4 Online Pharmacy
- 11.4.5 Others
- 11.5 Asia Pacific Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Country
- 11.5.1 China
- 11.5.2 Japan
- 11.5.3 India
- 11.5.4 ASEAN
- 11.5.5 Australia
- 11.5.6 Others
- 12 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (218-2034)
- 12.1 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 12.1.1 Market Overview
- 12.1.2 Arthritis
- 12.1.3 Migraine
- 12.1.4 Ophthalmic Diseases
- 12.1.5 Others
- 12.2 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 12.2.1 Over-the-Counter Drugs
- 12.2.1.1 Aspirin
- 12.2.1.2 Ibuprofen
- 12.2.1.3 Naproxen
- 12.2.1.4 Naproxen
- 12.2.1.5 Celecoxib
- 12.2.1.6 Others
- 12.2.2 Prescription
- 12.2.2.1 Daypro
- 12.2.2.2 Indocin
- 12.2.2.3 Lodine
- 12.2.2.4 Naprosyn
- 12.2.2.5 Relafen
- 12.2.2.6 Vimovo
- 12.2.2.7 Voltaren
- 12.3 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.4 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacy
- 12.4.3 Retail Pharmacy
- 12.4.4 Online Pharmacy
- 12.4.5 Others
- 12.5 Latin America Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Country
- 12.5.1 Brazil
- 12.5.2 Argentina
- 12.5.3 Mexico
- 12.5.4 Others
- 13 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (218-2034)
- 13.1 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Disease Indication
- 13.1.1 Market Overview
- 13.1.2 Arthritis
- 13.1.3 Migraine
- 13.1.4 Ophthalmic Diseases
- 13.1.5 Others
- 13.2 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Drugs
- 13.2.1 Over-the-Counter Drugs
- 13.2.1.1 Aspirin
- 13.2.1.2 Ibuprofen
- 13.2.1.3 Naproxen
- 13.2.1.4 Naproxen
- 13.2.1.5 Celecoxib
- 13.2.1.6 Others
- 13.2.2 Prescription
- 13.2.2.1 Daypro
- 13.2.2.2 Indocin
- 13.2.2.3 Lodine
- 13.2.2.4 Naprosyn
- 13.2.2.5 Relafen
- 13.2.2.6 Vimovo
- 13.2.2.7 Voltaren
- 13.3 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Parenteral
- 13.4 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Distribution Channels
- 13.4.1 Market Overview
- 13.4.2 Hospital Pharmacy
- 13.4.3 Retail Pharmacy
- 13.4.4 Online Pharmacy
- 13.4.5 Others
- 13.5 Middle East and Africa Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market (2018-2034) by Country
- 13.5.1 Saudi Arabia
- 13.5.2 United Arab Emirates
- 13.5.3 Nigeria
- 13.5.4 South Africa
- 13.5.5 Others
- 14 Regulatory Framework
- 14.1 Regulatory Overview
- 14.2 US FDA
- 14.3 EU EMA
- 14.4 INDIA CDSCO
- 14.5 JAPAN PMDA
- 14.6 Others
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Strategic Initiative
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1 Market Share Analysis: Global
- 17.1.2 Market Share Analysis: North America
- 17.1.3 Market Share Analysis: Europe
- 17.1.4 Market Share Analysis: Asia-Pacific
- 17.1.5 Market Share Analysis: Others
- 17.2 Assertio Holdings, Inc .
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Bayer AG
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Amgen Inc
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Lion Corporation
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Dr. Reddy’s Laboratories Ltd .
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Novartis AG
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Pfizer Inc .
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Johnson & Johnson Private Limited
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 GlaxoSmithKline plc
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Sanofi India Limited
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 18 Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
